blood group News
-
CD BioGlyco Now Provides Comprehensive Lectin Products for Glycobiology Research
CD BioGlyco, a worldwide biotechnology company, recently released a comprehensive list of lectin products, covering lectin, lectin buffers, lectin kits, lectin antibodies, lectin-coated microplates, as well as lectin columns, which can be served as robust tools for glycoproteins and carbohydrates study. Lectin refers to a glycoprotein or sugar-binding protein purified from various plants, ...
By CD BioGlyco.
-
Pollet Medical Group integrates Hemotech & Hema.T Medical
Pollet Medical Group, part of Pollet Group and mainly known for its water treatment activities under Pollet Water Group, integrates Hemotech & Hema.T Medical into their group. Both French companies are renomated experts in the market of hemodialysis and apheresis for dialysis centres and hospitals. Hemotech & Hema T. Medical deliver high quality medical devices intended to dialysis and ...
-
Air pollution from road traffic can raise blood pressure
High blood pressure is linked to long-term exposure to traffic-related air pollution, new research suggests. After accounting for lifestyle factors, socioeconomic status and pre-existing health conditions, the researchers found that a rise in traffic emissions of nitrogen dioxide corresponded to a rise in blood pressure of exposed individuals. Long-term exposure to air pollution has previously ...
-
PixCell Medical Partners with Triolab to Distribute Hematological Analyzer HemoScreen in Sweden
PixCell Medical, innovator of rapid diagnostic solutions at the point-ofcare, today announced a partnership with Triolab, the largest diagnostics distributor in the Nordic and Baltic countries, to be the sole distributor in Sweden of the HemoScreen™, PixCell’s hematology analyzer designed for use at the point of care. “PixCell’s HemoScreen brings lab-quality haematology ...
-
Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is expanding its scientific advisory board with the appointment of Jeff Sharman, M.D. and Clive Stanway, Ph.D. These two leaders in the field of cancer therapeutics will provide expert support and guidance as Araris continues preclinical and clinical development of its ...
-
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, CA and ST. LOUIS, MO, April 10, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 in pediatric acute lymphoblastic leukemia (T-ALL) ...
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...
-
Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
RURAL Cohort Study to Utilize PixCell Medical`s HemoScreen Hematology Analyzer for Research Initiative
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell's novel miniaturized, portable hematology analyzer, HemoScreen™, as part of its six year research study, aiming to gain insight into the specific health-related concerns of the rural southeastern United States' ...
-
Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart Platform, and selected as a Featured Company, in new report by MCD Group
New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group. The report, "Early Stage Drug ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Orchestra BioMed Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy
Double-blind, randomized trial data show a clinically meaningful and statistically significant net reduction of 8.1 mmHg in 24-hour ambulatory systolic blood pressure at 6 months in treated vs. control patients Very high (85%) response rate to therapy despite 81% of treated patients having isolated systolic hypertension (ISH), a more dangerous and difficult to treat form of hypertension ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you